Grant directory

Open

Pays entities up to $566,665 across three milestones to add shovel-ready cancer data or tools to NCI's CCDI ecosystem.

Pays tenure-track researchers up to $600,000 to build unproven cancer immunotherapy technology.

Open

Funds a continuation phase for medical research that already holds earlier DOD or DOW funding, from preclinical work through clinical trials.

Open

Funds pilot and feasibility work that prepares a spinal cord injury approach for a future, larger clinical trial.

Open

Funds a spinal cord injury clinical trial that opens with a pre-application stage and calls for named community partners throughout.

Open

Funds spinal cord injury research from basic science through translation, open to investigators at any career stage.

Open

Funds translational spinal cord injury research toward clinical use, with a named community partner and about $2.08 million per award on average.

Open

Funds a clinical trial for service-connected eye injury or visual dysfunction, with a regulatory clock that runs past the application deadline itself.

Open

Funds basic-through-early-translational research on service-connected eye injury or visual dysfunction — clinical trials are not part of this one.

Open

Funds translational work turning a vision-research discovery into a drug, device or guideline ready for a definitive clinical trial.

Open

Funds WARF-disclosed UW Madison inventions through patent and licensing preparation for market-ready transfer.

Open

Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.

Open

Funds Indigenous-led health research led by Aboriginal and Torres Strait Islander experts.

Open

Connects research teams and institutions for Interregional Innovation Investments Strand in manufacturing, materials science, and agriculture innovation.

Open

Funds EISMEA Interregional Innovation Investments for small and medium-sized enterprises in developing European regions through cross-border transfer and capability building.

Open

Funds three years replicating a natural product's effect on its target in people, for teams that have already done the pharmacokinetics work.

Open

Funds three years of pharmacokinetics and target-engagement work on a botanical, probiotic or supplement, then three more if the milestones are met.

Open

Funds the mid-phase study that settles a natural product's dose, formulation or responder group before anyone commits to a multi-site efficacy trial.

Open

Funds five university-based hubs that turn NIH-backed biomedical discoveries into products.

Open

Supports translational research for FASD prevention and intervention, moving through feasibility and expansion milestones.

Open

Single-step support for high-risk medical product development.

Open

Co-funds R&D projects between a Turkish customer company and an SME supplier, covering 40% of costs.

Open

Funds Swedish higher education institutions to host international researchers and strengthen global collaboration.

Open

Pays Dutch SME representative bodies to make their members' employee commuting greener.